Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy

By Frankenne F.   Noel A.   Bajou K.   Sounni N.   Goffin F.   Masson V.   Munaut C.   Remacle A.   Foidart J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 3, 1999-09 ,pp. : 469-481

Informa Healthcare

Access to resources Recommend Favorite

Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1970-1978

Bentham Science Publishers

Access to resources Recommend Favorite

3D-QSAR Studies on Isocoumarin-based Urokinase-type Plasminogen Activator (uPA) Inhibitors Employing Linear and Non-linear Regression Analysis Methods

By  

Letters in Drug Design & Discovery, Vol. 9, Iss. 9, 2012-11 ,pp. : 874-880

Bentham Science Publishers

Access to resources Recommend Favorite

Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-01 ,pp. : 1711-1728

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1890-1910

Bentham Science Publishers

Access to resources Recommend Favorite